Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISA-HC-NK
2024-514527-42-00Phase 2Authorised
- Sponsor
- Karolinska Institutet
- Start
- Sep 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in multiple myeloma (MM) comparing Isatuximab maintenance with Isatuximab + CellProtect maintenance (2 arms). Primary endpoint: Enhancement of Overall Response Rate (binary). Planned start Sep 2024; status: authorised.
02
Drugs
isatuximabCellProtect
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2024-514527-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514527-42-00.